Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19

Bibliographic Details
Main Authors:	Grégory Destras, Souad Assaad, Antonin Bal, Maude Bouscambert-Duchamp, Virginie Avrillon, Bruno Simon, Martine Valette, Jean-Yves Blay, Bruno Lina, Emilie Frobert, Laurence Josset
Format:	Article
Language:	English
Published:	Elsevier 2021-09-01
Series:	The Lancet Microbe
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666524721001890

Similar Items

SARS-CoV-2 Omicron Variant, Lineage BA.1, Is Associated with Lower Viral Load in Nasopharyngeal Samples Compared to Delta Variant
by: Célia Sentis, et al.
Published: (2022-04-01)

The NS Segment of H1N1pdm09 Enhances H5N1 Pathogenicity in a Mouse Model of Influenza Virus Infections
by: Olivier Ferraris, et al.
Published: (2018-09-01)

Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France
by: Grégory Quéromès, et al.
Published: (2021-01-01)

Performance Assessment of SARS-CoV-2 PCR Assays Developed by WHO Referral Laboratories
by: Sibyle Etievant, et al.
Published: (2020-06-01)

Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic
by: Grégory Destras, et al.
Published: (2020-08-01)

Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circulation in France
by: Antonin Bal, et al.
Published: (2022-10-01)

Performance of Self-Collected Saliva Testing Compared with Nasopharyngeal Swab Testing for the Detection of SARS-CoV-2
by: Florence Carrouel, et al.
Published: (2021-05-01)

Metagenomic Analysis Reveals High Abundance of Torque Teno Mini Virus in the Respiratory Tract of Children with Acute Respiratory Illness
by: Antonin Bal, et al.
Published: (2022-05-01)

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2
by: Nathan Peiffer-Smadja, et al.
Published: (2021-08-01)

Whole Genome Sequencing of A(H3N2) Influenza Viruses Reveals Variants Associated with Severity during the 2016–2017 Season
by: Bruno Simon, et al.
Published: (2019-01-01)

Correction: Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial.
by: Xavier Duval, et al.
Published: (2010-12-01)

Comparison of Nucleic Acid Extraction Methods for a Viral Metagenomics Analysis of Respiratory Viruses
by: Marina Sabatier, et al.
Published: (2020-10-01)

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
by: Xavier Duval, et al.
Published: (2010-11-01)

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial
by: Russell M. Nichols, et al.
Published: (2024-01-01)

SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy
by: Aurélie Truffot, et al.
Published: (2021-10-01)

Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients
by: Danny H. Pham, et al.
Published: (2021-12-01)

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together
by: C. Steven Ernest II, et al.
Published: (2022-06-01)

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
by: Kara W. Chew, et al.
Published: (2022-08-01)

Invasive actinomycosis: surrogate marker of a poor prognosis in immunocompromised patients
by: Isabelle Pierre, et al.
Published: (2014-12-01)

Metagenomic Investigation of Torque Teno Mini Virus-SH in Hematological Patients
by: Antonin Bal, et al.
Published: (2019-09-01)

Evaluation of Rapid Lateral-Flow Tests Directed against the SARS-CoV-2 Nucleoprotein Using Viral Suspensions Belonging to Different Lineages of SARS-CoV-2
by: Sylvie Pillet, et al.
Published: (2022-11-01)

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
by: Kara W. Chew, et al.
Published: (2023-01-01)

Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals
by: Faith C. Quenzer, et al.
Published: (2022-03-01)

Bamlanivimab Decreases Severe Outcomes of SARS-CoV-2 Infection in Patients With Antineutrophil Cytoplasmic Antibody Vasculitis
by: Jyotsna Ghosh, et al.
Published: (2022-03-01)

Long-term humoral response following Delta and Omicron BA.1 co-infection
by: Carla Saade, et al.
Published: (2023-04-01)

The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms
by: Robert W. Cross, et al.
Published: (2023-11-01)

Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses
by: Sydney I. Ramirez, et al.
Published: (2022-12-01)

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies
by: Erik Laurini, et al.
Published: (2021-10-01)

Evaluation of EPISEQ SARS-CoV-2 and a Fully Integrated Application to Identify SARS-CoV-2 Variants from Several Next-Generation Sequencing Approaches
by: Nathalie Mugnier, et al.
Published: (2022-07-01)

Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis
by: Yu-Lin Tai, et al.
Published: (2023-05-01)

Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region
by: Antonio Vena, et al.
Published: (2021-10-01)

Impact of the Respiratory Microbiome on Host Responses to Respiratory Viral Infection
by: Maxime Pichon, et al.
Published: (2017-11-01)

Lung Ultrasound Is Useful for Evaluating Lung Damage in COVID-19 Patients Treated with Bamlanivimab and Etesevimab: A Single-Center Pilot Study
by: Sebastiano Cicco, et al.
Published: (2023-01-01)

Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report
by: Rajapillai L. I. Pillai, et al.
Published: (2023-02-01)

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
by: Haolin Liu, et al.
Published: (2021-01-01)

Antiviral prophylaxis for varicella zoster in immunocompromised patients (excluding haematological malignancies)
by: Chang, C, et al.
Published: (2009)

SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab
by: Martin Heller, et al.
Published: (2023-04-01)

Impact of the H274Y Substitution on N1, N4, N5, and N8 Neuraminidase Enzymatic Properties and Expression in Reverse Genetic Influenza A Viruses
by: Alexandre Gaymard, et al.
Published: (2024-03-01)

SARS-CoV-2 N-Antigen Quantification in Respiratory Tract, Plasma and Urine: Kinetics and Association with RT-qPCR Results
by: Delphine Parraud, et al.
Published: (2023-04-01)

Novel SARS-CoV-2 Variant Derived from Clade 19B, France
by: Slim Fourati, et al.
Published: (2021-05-01)